Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 1
2020 3
2021 6
2022 2
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez-Villacampa MM, Nadal E, Bruna J. Velasco R, et al. Among authors: vilarino n. JAMA Neurol. 2021 Jul 1;78(7):864-873. doi: 10.1001/jamaneurol.2021.0249. JAMA Neurol. 2021. PMID: 33720308
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E, Rodríguez-Abreu D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Nadal E, et al. Among authors: vilarino n. J Clin Oncol. 2023 Oct 1;41(28):4478-4485. doi: 10.1200/JCO.22.02561. Epub 2023 Aug 21. J Clin Oncol. 2023. PMID: 37603816 Free PMC article. Clinical Trial.
Targeting molecular alterations in non-small-cell lung cancer: what's next?
López-Castro R, García-Peña T, Mielgo-Rubio X, Riudavets M, Teixidó C, Vilariño N, Couñago F, Mezquita L. López-Castro R, et al. Among authors: vilarino n. Per Med. 2022 Jul;19(4):341-359. doi: 10.2217/pme-2021-0059. Epub 2022 Jun 24. Per Med. 2022. PMID: 35748237 Review.
PD-L1 expression testing in non-small cell lung cancer.
Teixidó C, Vilariño N, Reyes R, Reguart N. Teixidó C, et al. Among authors: vilarino n. Ther Adv Med Oncol. 2018 Apr 11;10:1758835918763493. doi: 10.1177/1758835918763493. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29662547 Free PMC article. Review.
Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.
Martínez-Bosch N, Vilariño N, Alameda F, Mojal S, Arumí-Uria M, Carrato C, Aldecoa I, Ribalta T, Vidal N, Bellosillo B, Menéndez S, Del Barco S, Gallego O, Pineda E, López-Martos R, Hernández A, Mesia C, Esteve-Codina A, de la Iglesia N, Balañá C, Martínez-García M, Navarro P. Martínez-Bosch N, et al. Among authors: vilarino n. Cells. 2023 Mar 8;12(6):843. doi: 10.3390/cells12060843. Cells. 2023. PMID: 36980184 Free PMC article.
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications.
Hijazo-Pechero S, Alay A, Cordero D, Marín R, Vilariño N, Palmero R, Brenes J, Montalban-Casafont A, Nadal E, Solé X. Hijazo-Pechero S, et al. Among authors: vilarino n. Mol Oncol. 2024 Feb;18(2):453-470. doi: 10.1002/1878-0261.13550. Epub 2023 Dec 21. Mol Oncol. 2024. PMID: 37943164 Free PMC article.
21 results